Research Labs

Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.

Chemical biologist Daniel Bachovchin designs selective inhibitors to study enzymes and pathways in cancer and immune system signaling.

Sean Brady's research interests center on both the discovery and the functional characterization of new small molecules from previously inaccessible genetic sources.

Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.

The Chiosis lab uses a unique chemical biology approach to understand, diagnose, and treat cellular processes associated with chronic molecular stress, with the ultimate goal of developing novel therapeutic options for use in the clinic.

Jonathan Coleman is a physician-scientist focused on translational research, cancer genomics, and patient-derived organoid models in the study of urologic malignancies. Ongoing work includes the development of local ablative therapies, their influence on the tumor microenvironment, and implications for therapy response.

Physician-scientist Aimee Crago studies mechanisms by which common genomic events drive initiation and progression of soft tissue tumors.

My research involves the elucidation of genetic and biologic insights of human malignant lymphomas. We leverage large-scale unbiased profiling including genomics, transcriptomics, proteomics to identify candidate oncogenes and proteins that are pathogenetically relevant in lymphoma. We utilize molecular technologies, human tumor tissues and patient-derived xenografts and transgenic animal models to determine the functional significance of novel genes and proteins involved in lymphoma pathogenesis. Using primary tumors as our discovery models, the overall goal of our studies is to understand novel mechanisms of oncogenesis, identify tumor biomarkers and vulnerabilities that will facilitate early detection and precision therapies that improve patient outcomes.

Physician-scientist James Fagin focuses on the pathogenesis of thyroid cancer and the role of oncogenic kinases.